EE03423B1 - Kopolümeer-1, selle valmistamismeetod ja seda sisaldavad kompositsioonid - Google Patents
Kopolümeer-1, selle valmistamismeetod ja seda sisaldavad kompositsioonidInfo
- Publication number
- EE03423B1 EE03423B1 EE9600170A EE9600170A EE03423B1 EE 03423 B1 EE03423 B1 EE 03423B1 EE 9600170 A EE9600170 A EE 9600170A EE 9600170 A EE9600170 A EE 9600170A EE 03423 B1 EE03423 B1 EE 03423B1
- Authority
- EE
- Estonia
- Prior art keywords
- copolymer
- compositions
- preparation
- kilodaltons
- species
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rehabilitation Therapy (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Polyamides (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24803794A | 1994-05-24 | 1994-05-24 | |
US34424894A | 1994-11-23 | 1994-11-23 | |
PCT/US1995/006551 WO1995031990A1 (en) | 1994-05-24 | 1995-05-23 | Copolymer-1 improvements in compositions of copolymers |
Publications (2)
Publication Number | Publication Date |
---|---|
EE9600170A EE9600170A (et) | 1997-06-16 |
EE03423B1 true EE03423B1 (et) | 2001-06-15 |
Family
ID=26939072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EE9600170A EE03423B1 (et) | 1994-05-24 | 1995-05-23 | Kopolümeer-1, selle valmistamismeetod ja seda sisaldavad kompositsioonid |
Country Status (31)
Country | Link |
---|---|
US (11) | US5800808A (zh) |
EP (1) | EP0762888B1 (zh) |
JP (2) | JPH10500955A (zh) |
KR (1) | KR100403750B1 (zh) |
CN (2) | CN1174753C (zh) |
AT (1) | ATE212857T1 (zh) |
AU (1) | AU2602195A (zh) |
BR (2) | BR9507758A (zh) |
CA (1) | CA2191088C (zh) |
CZ (1) | CZ292247B6 (zh) |
DE (2) | DE10299030I1 (zh) |
DK (1) | DK0762888T3 (zh) |
EE (1) | EE03423B1 (zh) |
ES (1) | ES2172586T3 (zh) |
FI (1) | FI120236B (zh) |
GE (1) | GEP20002205B (zh) |
HK (1) | HK1008657A1 (zh) |
HU (1) | HU223473B1 (zh) |
IL (2) | IL113812A (zh) |
LU (1) | LU90987I2 (zh) |
MD (1) | MD1443G2 (zh) |
NL (1) | NL300096I2 (zh) |
NO (1) | NO324528B1 (zh) |
NZ (1) | NZ287335A (zh) |
PL (1) | PL181026B1 (zh) |
PT (1) | PT762888E (zh) |
SI (1) | SI0762888T1 (zh) |
SK (1) | SK283699B6 (zh) |
TJ (1) | TJ392B (zh) |
UA (1) | UA62908C2 (zh) |
WO (1) | WO1995031990A1 (zh) |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077509A (en) * | 1990-03-30 | 2000-06-20 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
US7090982B2 (en) | 1991-10-22 | 2006-08-15 | The Governors Of The University Of Alberta | Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient |
US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
US5858964A (en) * | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
IL119989A0 (en) * | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
KR20010052170A (ko) * | 1998-02-13 | 2001-06-25 | 오토이뮨, 인코포레이티드 | COP-1 및 Th2-증진 시토킨류를 이용한 다발성경화증의 치료 방법 |
EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES |
WO2000005249A2 (en) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
WO2000018794A1 (en) | 1998-09-25 | 2000-04-06 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
WO2000020010A1 (en) * | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
US7083777B1 (en) | 1999-04-02 | 2006-08-01 | The Brigham And Women's Hospital, Inc. | Immunomodulating polymers |
AU780188B2 (en) * | 2000-01-20 | 2005-03-03 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
US7022663B2 (en) * | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
IL150895A0 (en) * | 2000-02-18 | 2003-02-12 | Teva Pharma | Oral, nasal and pulmonary formulations of copolymer-1 |
CA2411536A1 (en) * | 2000-06-05 | 2001-12-13 | V. Wee Yong | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
ATE314860T1 (de) * | 2000-06-07 | 2006-02-15 | Yeda Res & Dev | Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet |
IL148202A0 (en) * | 2000-06-20 | 2002-09-12 | Caprion Pharmaceuticals Inc | Copolymers and methods of treating prion-related diseases |
WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
IL137460A0 (en) | 2000-07-24 | 2001-07-24 | Yeda Res & Dev | Identifying antigen clusters for monitoring a global state of an immune system |
US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
SV2003000753A (es) | 2000-12-05 | 2003-06-16 | Brigham & Womens Hospital | Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico |
GB2369896A (en) | 2000-12-06 | 2002-06-12 | Marconi Comm Ltd | Tunable optical filter actuator |
KR100442122B1 (ko) * | 2001-07-31 | 2004-07-30 | 한국전기연구원 | 영구 자석을 이용한 브러시리스 발전기 |
ES2349033T3 (es) * | 2001-12-04 | 2010-12-22 | Teva Pharmaceutical Industries, Ltd. | Procedimientos para la medida de la actividad del acetato de glatiramer. |
IL160105A0 (en) * | 2001-12-06 | 2004-06-20 | Yeda Res & Dev | Vaccine for treatment of motor neurone diseases |
AU2002360696A1 (en) * | 2001-12-21 | 2003-07-30 | Ilex Oncology, Inc. | Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis |
AU2004203772B2 (en) | 2003-01-07 | 2009-07-16 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
MXPA05007711A (es) * | 2003-01-21 | 2005-09-30 | Yeda Res & Dev | Copolimero 1 para el tratamiento de enfermedades inflamatorias del intestino. |
CA2518079A1 (en) * | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
JP2006522135A (ja) | 2003-03-31 | 2006-09-28 | ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド | 喘息およびアレルギーの処置のための両性イオン免疫調節剤 |
CA2541445A1 (en) * | 2003-10-31 | 2005-05-12 | Teva Pharmaceutical Industries Ltd. | Nanoparticles for drug delivery |
AU2004288654B2 (en) | 2003-11-12 | 2009-12-03 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
EP1701730B1 (en) | 2003-12-09 | 2013-08-21 | Yeda Research And Development Co., Ltd. | Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders |
US20090214580A1 (en) * | 2004-02-02 | 2009-08-27 | Houghten Richard A | Peptide mixtures with immunomodulatory activity |
RU2006134701A (ru) * | 2004-03-01 | 2008-04-10 | Пептиммьюн | Способы и композиции для лечения аутоиммунных заболеваний |
CA2558380A1 (en) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
US20050260770A1 (en) * | 2004-04-01 | 2005-11-24 | Cohen Irun R | Antigen array and diagnostic uses thereof |
US20060194725A1 (en) * | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
US7655221B2 (en) * | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
WO2005112972A1 (en) | 2004-05-07 | 2005-12-01 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
SG153871A1 (en) | 2004-06-25 | 2009-07-29 | Id Biomedical Corp Quebec | Compositions and methods for treating neurological disorders |
PT2361924E (pt) * | 2004-09-09 | 2014-03-13 | Teva Pharma | Processo para a preparação de misturas de acetato de glatirâmero trifluoroacetiílico utilizando ácido bromídrico purificado |
PL1797109T3 (pl) * | 2004-09-09 | 2016-11-30 | Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania | |
US8324641B2 (en) * | 2007-06-29 | 2012-12-04 | Ledengin, Inc. | Matrix material including an embedded dispersion of beads for a light-emitting device |
JP5297653B2 (ja) * | 2004-10-29 | 2013-09-25 | サンド・アクチエンゲゼルシヤフト | グラチラマーの製造法 |
US20090191173A1 (en) * | 2004-11-29 | 2009-07-30 | Michal Eisenbach-Schwartz | Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1 |
RU2419638C2 (ru) * | 2005-02-02 | 2011-05-27 | Тева Фармасьютикал Индастриз, Лтд. | Способ получения полипептидных смесей с использованием гидрогенолиза |
US20100167983A1 (en) * | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
SI1848415T1 (sl) * | 2005-02-17 | 2013-08-30 | Teva Pharmaceutical Industries Ltd. | Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze |
US20060240463A1 (en) * | 2005-04-25 | 2006-10-26 | Rappaport Family Institute For Research In The Medical Sciences | Markers associated with the therapeutic efficacy of glatiramer acetate |
US20070161566A1 (en) * | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
WO2007092451A2 (en) | 2006-02-06 | 2007-08-16 | The Brigham And Women's Hospital, Inc. | Zwitterionic polysaccharides for promotion of immune system maturation and health |
EP2016095A2 (en) | 2006-04-13 | 2009-01-21 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
JP5374363B2 (ja) | 2006-04-28 | 2013-12-25 | モメンタ ファーマシューティカルズ インコーポレイテッド | ペプチド混合物を評価する方法 |
KR100831796B1 (ko) * | 2006-05-29 | 2008-05-28 | 엘지전자 주식회사 | 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법 |
JP5412280B2 (ja) | 2006-06-28 | 2014-02-12 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 加齢性黄斑変性症の治療法 |
DE602007003848D1 (de) * | 2006-07-05 | 2010-01-28 | Momenta Pharmaceuticals Inc | Verbessertes verfahren zur herstellung von copolymer-1 |
EP2174130A2 (en) | 2007-06-21 | 2010-04-14 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
US20090029766A1 (en) * | 2007-07-26 | 2009-01-29 | Lutnick Howard W | Amusement gaming access and authorization point |
CA2705046C (en) * | 2007-07-31 | 2015-03-03 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
EP2207566A1 (en) | 2007-10-16 | 2010-07-21 | Peptimmune, Inc. | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
JP2011503104A (ja) | 2007-11-09 | 2011-01-27 | カリフォルニア インスティテュート オブ テクノロジー | 免疫調節化合物ならびに関連組成物および方法 |
AU2008330093A1 (en) * | 2007-11-28 | 2009-06-04 | Yeda Research And Development Co., Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
EP2277050B2 (en) * | 2008-04-16 | 2022-09-28 | Momenta Pharmaceuticals, Inc. | Analysis of amino acid copolymer compositions |
EP2307448B1 (en) * | 2008-08-07 | 2015-04-22 | Sigma-Aldrich Co. LLC | Preparation of low molecular weight polylysine and polyornithine in high yield |
KR20110059606A (ko) * | 2008-08-07 | 2011-06-02 | 시노팜 타이완 리미티드 | 글라티라머 아세테이트의 합성 |
US9617313B2 (en) | 2008-12-24 | 2017-04-11 | Synthon Bv | Process for purifying a polymer mixture |
ES2523732T5 (es) * | 2009-04-03 | 2023-10-23 | Momenta Pharmaceuticals Inc | Control de composiciones de copolímeros |
WO2010140157A1 (en) * | 2009-06-04 | 2010-12-09 | Council Of Scientific & Industrial Research | Aprocess for the preparation of copolymer - 1 (cop-i), composed of l-alanine, l-lysine, l-glutamic acid and l-tyrosine-drug for the treatment of multiple sclerosis |
US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
DK2275086T3 (da) * | 2009-07-15 | 2012-07-09 | Teva Pharma | Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf |
US8691790B2 (en) * | 2009-07-27 | 2014-04-08 | James Layne Boucher | Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy |
PL2949335T3 (pl) | 2009-08-20 | 2017-07-31 | Yeda Research & Development Company, Ltd. | Terapia octanem glatirameru podawanym z niewielką częstotliwością |
CA2784394C (en) | 2010-01-04 | 2016-12-13 | Mapi Pharma Limited | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
WO2011086470A1 (en) | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
HUE040658T2 (hu) | 2010-04-07 | 2019-03-28 | California Inst Of Techn | Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek |
MX2012012489A (es) * | 2010-04-27 | 2012-12-17 | Reddys Lab Ltd Dr | Preparacion de polipeptidos y sales de los mismos. |
EP2571982A4 (en) | 2010-05-20 | 2014-01-01 | California Inst Of Techn | ANTIGEN-SPECIFIC TREGS AND CORRESPONDING COMPOSITIONS, METHODS AND SYSTEMS |
BR112013002230A2 (pt) * | 2010-07-29 | 2016-05-24 | Reddys Lab Inc Dr | marcadores de peso molecular de acetato de glatiramer |
MX347871B (es) | 2010-10-11 | 2017-05-16 | Teva Pharmaceutical Ind Ltd * | Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero. |
RU2604521C2 (ru) | 2011-02-14 | 2016-12-10 | Юсв Прайвит Лимитед | Сополимер-1, способы его получения и аналитические методы |
EP2699317B1 (en) * | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
WO2012150495A1 (en) | 2011-05-05 | 2012-11-08 | National Institute Of Immunology | Synthetic peptides and random copolymers for the treatment of autoimmune disorders |
WO2013009885A2 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Evaluation of copolymer diethylamide |
WO2013009864A1 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Structure assessment of heterogeneous polypeptide mixtures |
US9539281B2 (en) | 2011-07-12 | 2017-01-10 | The Brigham And Women's Hospital, Inc. | Lipid-containing PSA compositions, methods of isolation and methods of use thereof |
US8575198B1 (en) | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
AU2012323345A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
WO2013139728A1 (en) | 2012-03-19 | 2013-09-26 | Synthon Bv | Glatiramer acetate human monocyte cell-based potency assay |
EP2642290A1 (en) | 2012-03-19 | 2013-09-25 | Synthon BV | Glatiramer acetate human monocytic cell line-based potency assay |
US20140045740A1 (en) * | 2012-08-13 | 2014-02-13 | Momenta Pharmaceuticals, Inc. | Analysis of glatiramer acetate |
US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
WO2014060942A2 (en) * | 2012-10-20 | 2014-04-24 | Mahesh Kandula | Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases |
WO2014128079A1 (en) | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
ES2529242T3 (es) | 2013-03-08 | 2015-02-18 | Teva Pharmaceutical Industries, Ltd. | Dispositivo inyector reutilizable para jeringuilla |
RS53741B1 (en) | 2013-03-08 | 2015-06-30 | Teva Pharmaceutical Industries Ltd. | Injectable Reusable Injection Device |
EP2971173A4 (en) | 2013-03-14 | 2016-11-23 | Mylan Inc | GLATIRAMERATE ACETATE POWER TEST BY MRM RESPONSE BIOMARKERS |
WO2014173463A1 (en) | 2013-04-26 | 2014-10-30 | Synthon Bv | Glatiramer acetate human monocytic cell line-based potency assay |
WO2014182966A1 (en) | 2013-05-10 | 2014-11-13 | California Institute Of Technology | Probiotic prevention and treatment of colon cancer |
CN103265624B (zh) * | 2013-05-27 | 2015-04-22 | 成都圣诺生物制药有限公司 | 格拉替雷的制备方法 |
CN104371012A (zh) * | 2013-08-12 | 2015-02-25 | 深圳翰宇药业股份有限公司 | 一种合成醋酸格拉替雷的方法 |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
WO2015061610A2 (en) * | 2013-10-24 | 2015-04-30 | Mylan Inc. | Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations |
WO2015101988A1 (en) | 2013-12-31 | 2015-07-09 | Yeda Research And Development Co. Ltd. | Diagnosis of systemic lupus erythematosus using oligonucleotides antigens |
JP6903432B2 (ja) | 2014-03-12 | 2021-07-14 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Cnsの疾患および傷害を処置するために全身性調節性t細胞のレベルまたは活性を低下させること |
CN104844697B (zh) | 2014-09-26 | 2018-10-23 | 深圳翰宇药业股份有限公司 | 醋酸格拉替雷的制备方法 |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
WO2016139659A1 (en) | 2015-03-01 | 2016-09-09 | Immunarray Ltd. | Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens |
US11331335B2 (en) | 2015-06-10 | 2022-05-17 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
WO2017031431A1 (en) | 2015-08-19 | 2017-02-23 | President And Fellows Of Harvard College | Lipidated psa compositions and methods |
ES2744179T3 (es) | 2015-09-24 | 2020-02-24 | Chemi Spa | Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas |
EP3170836B1 (en) | 2015-11-23 | 2018-10-24 | Chemi SPA | Rp-hplc analysis of complex polypeptide mixtures |
CN107522774B (zh) * | 2016-06-22 | 2021-07-02 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法 |
EP3478300B1 (en) | 2016-06-30 | 2022-08-24 | Stem Cell Medicine Ltd. | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells |
US11491181B2 (en) | 2016-07-15 | 2022-11-08 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
EP3503907B1 (en) | 2016-08-28 | 2024-03-13 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
JP7193448B2 (ja) | 2016-08-31 | 2022-12-20 | マピ ファーマ リミテッド | 酢酸グラチラマーを含むデポシステム |
CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
US11510946B2 (en) | 2017-05-15 | 2022-11-29 | Stem Cell Medicine Ltd. | Treatment of multiple sclerosis with adipose-derived stem cells |
CA3062964A1 (en) | 2017-05-15 | 2018-11-22 | Stem Cell Medicine Ltd. | Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells |
EP3765034A1 (en) | 2018-03-12 | 2021-01-20 | Yeda Research and Development Co. Ltd | Treatment of a heart disease |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
US4444760A (en) * | 1983-06-17 | 1984-04-24 | Merck & Co., Inc. | Purification and characterization of a protein fibroblast growth factor |
JPS6053535A (ja) | 1983-09-02 | 1985-03-27 | Nitto Boseki Co Ltd | 規則性ポリアミノ酸樹脂の製造方法 |
SU1182051A1 (ru) | 1984-04-28 | 1985-09-30 | Таджикский государственный университет им.В.И.Ленина | Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина |
AU596986B2 (en) | 1985-06-18 | 1990-05-24 | Emory University | Biologically-active copolymers |
DD257174A3 (de) | 1985-12-20 | 1988-06-08 | Ve Forschungszentrum Biotechno | Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease |
SU1469826A1 (ru) | 1986-05-30 | 1995-11-20 | Институт Высокомолекулярных Соединений Ан Ссср | Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения |
US4828706A (en) * | 1988-03-07 | 1989-05-09 | Spectrum Medical Industries | Process for performing a dialysis operation |
US4908404A (en) * | 1988-08-22 | 1990-03-13 | Biopolymers, Inc. | Synthetic amino acid-and/or peptide-containing graft copolymers |
DE8900366U1 (zh) * | 1989-01-13 | 1989-08-03 | Indag Gesellschaft Fuer Industriebedarf Mbh, 6904 Eppelheim, De | |
CA2009996A1 (en) * | 1989-02-17 | 1990-08-17 | Kathleen S. Cook | Process for making genes encoding random polymers of amino acids |
SU1690368A1 (ru) | 1989-07-20 | 1995-08-20 | Институт Высокомолекулярных Соединений Ан Ссср | Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения |
DE3930733A1 (de) | 1989-09-14 | 1991-03-28 | Roehm Gmbh | Verfahren zur herstellung eines komplexierten arzneimittels |
JP2653255B2 (ja) * | 1990-02-13 | 1997-09-17 | 武田薬品工業株式会社 | 長期徐放型マイクロカプセル |
DE69228254T2 (de) * | 1991-11-12 | 1999-08-19 | Du Pont | Kollagenartige polypeptide |
IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
JP2001524011A (ja) | 1997-05-06 | 2001-11-27 | クワンタ・ビジョン | 組織分析装置 |
AU780188B2 (en) * | 2000-01-20 | 2005-03-03 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
US6936539B2 (en) * | 2003-09-24 | 2005-08-30 | Micron Technology, Inc. | Antireflective coating for use during the manufacture of a semiconductor device |
-
1995
- 1995-05-22 IL IL11381295A patent/IL113812A/xx not_active IP Right Cessation
- 1995-05-22 US US08/447,146 patent/US5800808A/en not_active Expired - Lifetime
- 1995-05-23 DE DE2002199030 patent/DE10299030I1/de active Pending
- 1995-05-23 WO PCT/US1995/006551 patent/WO1995031990A1/en active IP Right Grant
- 1995-05-23 EE EE9600170A patent/EE03423B1/xx unknown
- 1995-05-23 CA CA002191088A patent/CA2191088C/en not_active Expired - Lifetime
- 1995-05-23 BR BR9507758A patent/BR9507758A/pt active IP Right Grant
- 1995-05-23 ES ES95920632T patent/ES2172586T3/es not_active Expired - Lifetime
- 1995-05-23 PL PL95317331A patent/PL181026B1/pl unknown
- 1995-05-23 CZ CZ19963410A patent/CZ292247B6/cs not_active IP Right Cessation
- 1995-05-23 HU HU9603243A patent/HU223473B1/hu active Protection Beyond IP Right Term
- 1995-05-23 PT PT95920632T patent/PT762888E/pt unknown
- 1995-05-23 CN CNB951941011A patent/CN1174753C/zh not_active Expired - Lifetime
- 1995-05-23 SK SK1493-96A patent/SK283699B6/sk not_active IP Right Cessation
- 1995-05-23 MD MD97-0024A patent/MD1443G2/ro unknown
- 1995-05-23 JP JP7530519A patent/JPH10500955A/ja active Pending
- 1995-05-23 GE GEAP19953466A patent/GEP20002205B/en unknown
- 1995-05-23 AT AT95920632T patent/ATE212857T1/de active
- 1995-05-23 DK DK95920632T patent/DK0762888T3/da active
- 1995-05-23 CN CNB200410064296XA patent/CN1310673C/zh not_active Expired - Lifetime
- 1995-05-23 KR KR1019960706612A patent/KR100403750B1/ko not_active IP Right Cessation
- 1995-05-23 DE DE69525340T patent/DE69525340T2/de not_active Expired - Lifetime
- 1995-05-23 EP EP95920632A patent/EP0762888B1/en not_active Expired - Lifetime
- 1995-05-23 SI SI9530577T patent/SI0762888T1/xx unknown
- 1995-05-23 UA UA96114382A patent/UA62908C2/uk unknown
- 1995-05-23 BR BRPI9507758-8A patent/BRPI9507758B1/pt unknown
- 1995-05-23 NZ NZ287335A patent/NZ287335A/xx not_active IP Right Cessation
- 1995-05-23 TJ TJ96000421A patent/TJ392B/xx unknown
- 1995-05-23 AU AU26021/95A patent/AU2602195A/en not_active Abandoned
-
1996
- 1996-11-15 FI FI964600A patent/FI120236B/fi not_active IP Right Cessation
- 1996-11-22 NO NO19964976A patent/NO324528B1/no not_active IP Right Cessation
-
1998
- 1998-02-27 US US09/032,647 patent/US6054430A/en not_active Expired - Lifetime
- 1998-02-27 US US09/032,616 patent/US5981589A/en not_active Expired - Lifetime
- 1998-02-27 US US09/032,334 patent/US6048898A/en not_active Expired - Lifetime
- 1998-07-02 HK HK98108818A patent/HK1008657A1/xx not_active IP Right Cessation
-
2000
- 2000-01-05 IL IL13389000A patent/IL133890A0/xx not_active IP Right Cessation
- 2000-02-22 US US09/510,141 patent/US6342476B1/en not_active Expired - Lifetime
- 2000-02-22 US US09/510,466 patent/US6362161B1/en not_active Expired - Lifetime
-
2001
- 2001-12-14 US US10/014,477 patent/US6620847B2/en not_active Expired - Lifetime
-
2002
- 2002-07-29 NL NL300096C patent/NL300096I2/nl unknown
- 2002-08-05 LU LU90987C patent/LU90987I2/fr unknown
- 2002-08-09 JP JP2002233094A patent/JP3715600B2/ja not_active Expired - Lifetime
-
2003
- 2003-07-10 US US10/615,865 patent/US6939539B2/en not_active Expired - Lifetime
-
2005
- 2005-04-05 US US11/098,432 patent/US7199098B2/en not_active Expired - Fee Related
-
2007
- 2007-01-23 US US11/656,505 patent/US7625861B2/en not_active Expired - Fee Related
-
2011
- 2011-09-26 US US13/244,737 patent/US8367605B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE03423B1 (et) | Kopolümeer-1, selle valmistamismeetod ja seda sisaldavad kompositsioonid | |
PE14199A1 (es) | Agonistas de 5-ht1f | |
EP0590071A4 (en) | Substantially pure receptor like tgf--g(b)1 binding molecules and uses thereof | |
EA200200479A1 (ru) | Новые олигосахариды, их получение и содержащие их фармацевтические композиции | |
ATE229340T1 (de) | Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen | |
BG103872A (en) | Glycoconjugates of 20(s)-camptotecin | |
SE9602822D0 (sv) | New receptor | |
ATE130289T1 (de) | 1,3-diphenyl-2-propin-1-one. | |
SE9604439D0 (sv) | New receptor | |
MD1278F1 (en) | Liqueur composition | |
MX9605048A (es) | Gonadotropinas con puentes de disulfuros no nativos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20021231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20031231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20091231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
QB4A | Licence registered |
Free format text: EXCLUSIVE LICENSE UNTIL TS KSELI Name of requester: TEVA PHARMACEUTICAL INDUSTRIES LTD. |